Daniel M. Halperin, MD
-
RoleMedical Oncology
-
Specialty
-
Research Program
-
Practicing Since2015
Background
A board-certified medical oncologist, Daniel M. Halperin, MD, specializes in the treatment of neuroendocrine tumors (NETs). Dr. Halperin is a physician on the gastrointestinal oncology team at Winship Cancer Institute of Emory University.
Dr. Halperin is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Medicine. As vice chair of clinical affairs, he works with the department chair and other leaders to plan, communicate and execute Winship strategies and organizational goals in the clinical arena, and to support and direct the performance of physician faculty members in the department.
Dr. Halperin received his medical degree from Weill Cornell Medical College in New York City, New York. He completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas.
Titles & Roles
-
Associate Professor, Department of Hematology and Medical OncologyEmory University School of Medicine
-
Vice Chair of Clinical Affairs, Department of Hematology and Medical OncologyEmory University School of Medicine
Education & Training
Education
- Fellowship, Hematology/Oncology, 2015University of Texas M. D. Anderson Cancer Center, Houston, TX
- Residency, Internal Medicine, 2012Brigham and Women's Hospital
- Internship, Internal Medicine, 2010Brigham and Women's Hospital
- Medical Education, MD, 2009Weill Cornell Medical College
Board Certifications
- Medical OncologyAmerican Board of Internal Medicine, 2015Internal MedicineAmerican Board of Internal Medicine, 2013
Professional Memberships
Dr. Halperin serves on the Board of Scientific Advisors of the NET Research Foundation, the Scientific Advisory Committee of the Healing NET Foundation and the Board of Directors and Symposium Committee of the North American Neuroendocrine Tumor Society.
Research
As a clinical investigator, Halperin is dedicated to providing world-class clinical care and developing novel therapies for patients with neuroendocrine tumors (NETs), which are tumors that develop from a diffuse network of neuroendocrine cells that make and release hormones into the bloodstream to control essential bodily functions. He has played a leading role in clinical trials of immunotherapy and radioligands for patients with NETs. He also collaborates with laboratory and population scientists to deepen our understanding of the molecular basis and clinical presentation of neuroendocrine tumors.
-
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
- PhaseIII
-
ConditionsCarcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
- LocationEmory University Hospital Midtown, Winship Cancer Institute
-
-
- PhaseI/II
-
ConditionsNeuroendocrine Tumors, Colorectal Cancer, Gastric Cancer
- LocationEmory University Hospital Midtown, Winship Cancer Institute
-
Publications
Title/Journal Authors Publication Date Epidemiology of Neuroendocrine Neoplasms in the US.
JAMA network open
A Dasari, K Wallace, DM Halperin, J Maxwell, P Kunz, S Singh, B Chasen, JC Yao 06/02/2025 Clinical cancer research : an official journal of the American Association for Cancer Research
VK Morris, S Liu, K Lin, H Zhu, S Prasad, A Mahvash, P Bhosale, B Sun, ER Parra, I Wistuba, A Peddireddy, J Yao, J Mendoza-Perez, M Knafl, SE Woodman, C Eng, D Halperin 05/01/2025 Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.
Future oncology (London, England)
US Grewal, OB Gbolahan, AM Takalkar, DM Halperin 05/01/2025 Journal of neuroendocrinology
MA Morse, EJ Crosby, DM Halperin, HE Uronis, SD Hsu, HI Hurwitz, C Rushing, EK Bolch, DA Warren, AN Moyer, ME Lowe, D Niedzwiecki 04/01/2025 Classification of Gastric Neuroendocrine Tumors and Associations With Survival.
Journal of surgical oncology
Y Song, E Chen, YJ Chiang, JC Yao, DM Halperin, D Chatterjee, BD Badgwell 02/01/2025 Cancers
D Bhamidipati, JR Johnson, K Lin, H Pelicano, C Eng, R Huey, RA Wolff, DM Halperin, MF Frumovitz, II Wistuba, DY Duose, S Mallampati, R Luthra, VK Morris 01/19/2025 Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
Clinical cancer research : an official journal of the American Association for Cancer Research
QH Meng, TR Halfdanarson, JA Bornhorst, H Jann, S Shaheen, RZ Shi, A Schwabe, K Stade, DM Halperin 12/16/2024 Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.
NPJ precision oncology
AG Serrano, P Rocha, C Freitas Lima, A Stewart, B Zhang, L Diao, J Fujimoto, RJ Cardnell, W Lu, K Khan, B Sable, AR Ellison, II Wistuba, KF Concannon, DM Halperin, C Bogdan, K Sircar, M Zhang, K Cargill, Q Wang, A Aparicio, A Lazar, S Hernandez, J Estrella, P Ramalingam, A El-Naggar, N Kalhor, CM Gay, LA Byers, LM Solis Soto 11/19/2024 Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors.
Current oncology reports
BC Fields, RI Ayabe, YD Seo, JE Maxwell, DM Halperin 11/01/2024 JAMA oncology
M Yousef, A Yousef, S Chowdhury, MM Fanaeian, M Knafl, J Peterson, M Zeineddine, K Alfaro, F Zeineddine, D Goldstein, N Hornstein, A Dasari, R Huey, B Johnson, V Higbie, A Bent, B Kee, M Lee, MP Morelli, VK Morris, D Halperin, MJ Overman, C Parseghian, E Vilar, R Wolff, KP Raghav, MG White, A Uppal, R Sun, W Wang, S Kopetz, J Willis, JP Shen 11/01/2024 Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
4.9 Provider showed concern 4.9 Provider explained things clearly 4.9 Provider discussed treatment options 4.9 Provider included you in decisions 4.9 Likelihood of recommending this provider